<DOC>
	<DOCNO>NCT00266279</DOCNO>
	<brief_summary>This phase II study test response rate combine oxaliplatin capecitabine treatment administer give dose schedule , patient Head Neck cancer curative treatment .</brief_summary>
	<brief_title>Phase II ( Treatment ) Study Oxaliplatin Capecitabine Advanced Head Neck Malignancies</brief_title>
	<detailed_description>The optimal dose schedule combine treatment oxaliplatin capecitabine define . The aim Phase II study determine response rate combine oxaliplatin capecitabine treatment give dose schedule patient Head Neck cancer curative treatment . The study also aim determine qualitative quantitative toxicity reversibility toxicity combination evaluate change performance status , quality life , overall survival progression-free survival .</detailed_description>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Patients must histologically cytologically confirm squamous cell cancer Head Neck Patients must metastatic locally recurrent disease Patients must disease curable surgery estimate one protocol investigator , eligible reradiation protocol fail reradiation protocol . Patients must measurable disease , define least one lesion accurately measure least one dimension ( long diameter record ) &gt; 20 mm conventional technique &gt; 10 mm spiral CT scan Age &gt; 18 year age Life expectancy great 12 week ECOG performance status 0 , 1 2 ( Karnofsky &gt; 50 % ; see Appendix B ) Patients must adequate bone marrow function define : absolute neutrophil count &gt; 1,500 platelet &gt; 100,000 hemoglobin &gt; 8 g/dl Patients must adequate renal function define creatinine clearance &gt; 30 mL/min ( measure estimate Cockroft Gault equation ) Cockroft Gault equation : Creatinine clearance male = ( 140age [ yr ] ) ( body wt [ kg ] ) /72 ( serum creatinine [ mg/dL ] ) Creatinine clearance female = 0.85 x male value Patients must adequate liver function define : total bilirubin 1.5x upper limit normal albumin &gt; 2.5 g/dl AST ( SGOT ) ALT ( SGPT ) Alkaline Phosphatase must &lt; 5 time upper limit normal Patients could receive 1 2 previous chemotherapy regimens prior enter study . Patients must recover acute toxicity chemotherapy radiotherapy administer prior enter study . Alopecia may resolve peripheral neuropathy ( grade 1 ) may present . Patients reproductive potential must use adequate contraceptive method ( e.g. , abstinence , intrauterine device , oral contraceptive , barrier device spermicide surgical sterilization ) treatment three month complete treatment . Ability understand willingness sign write informed consent document Prior unanticipated severe reaction fluoropyrimidine therapy know hypersensitivity 5fluorouracil oxaliplatin Patients chemotherapy radiotherapy within 4 week prior first treatment study recover adverse event due agent administer 4 week earlier Patients receive investigational agent ( ) Patients symptomatic brain metastasis actively receive therapy brain metastasis ( poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic adverse event ) Active second malignancy last 5 year except nonmelanoma skin cancer carcinomainsitu Clinically significant cardiac disease ( e.g . congestive heart failure , New York Heart Association Class II great , symptomatic coronary artery disease cardiac arrhythmia ) myocardial infarction within last 12 month . If patient unable swallow , xeloda may crush per hospital policy/procedure . See attached Appendix G. Patients organ allograft . Uncontrolled intercurrent illness include , limited , ongoing active infection , psychiatric illness/social situation would limit compliance study requirement . Pregnancy Known Hepatitis B , Hepatitis C , HIV Inclusion Minorities : Members ethnic group eligible trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>